Algorae Pharmaceuticals Ltd (1AI) - Total Liabilities
Based on the latest financial reports, Algorae Pharmaceuticals Ltd (1AI) has total liabilities worth AU$111.25K AUD (≈ $78.72K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 1AI long-term investments to assets to see how much of total assets are deployed in long-term investments.
Algorae Pharmaceuticals Ltd - Total Liabilities Trend (2004–2025)
This chart illustrates how Algorae Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Algorae Pharmaceuticals Ltd total assets.
Algorae Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Algorae Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Raspberry Pi Holdings PLC
LSE:RPI
|
UK | GBX67.51 Million |
|
OpTeam S.A.
WAR:OPM
|
Poland | zł25.66 Million |
|
AHB Holdings Bhd
KLSE:7315
|
Malaysia | RM854.15K |
|
Quality Concrete Holdings Bhd
KLSE:7544
|
Malaysia | RM199.00 Million |
|
Emova Group SA
PA:ALEMV
|
France | €42.01 Million |
|
Falcon Power Co Ltd
TW:1516
|
Taiwan | NT$2.57 Million |
|
Majuperak Holdings Bhd
KLSE:8141
|
Malaysia | RM139.77 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Algorae Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 1AI net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Algorae Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Algorae Pharmaceuticals Ltd (2004–2025)
The table below shows the annual total liabilities of Algorae Pharmaceuticals Ltd from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$169.76K ≈ $120.11K |
-4.87% |
| 2024-06-30 | AU$178.45K ≈ $126.26K |
-60.33% |
| 2023-06-30 | AU$449.86K ≈ $318.30K |
+88.02% |
| 2022-06-30 | AU$239.26K ≈ $169.29K |
-9.74% |
| 2021-06-30 | AU$265.08K ≈ $187.56K |
-48.30% |
| 2020-06-30 | AU$512.72K ≈ $362.78K |
-68.37% |
| 2019-06-30 | AU$1.62 Million ≈ $1.15 Million |
+242.39% |
| 2018-06-30 | AU$473.47K ≈ $335.01K |
-59.74% |
| 2017-06-30 | AU$1.18 Million ≈ $832.11K |
+84.97% |
| 2016-06-30 | AU$635.80K ≈ $449.87K |
+88.30% |
| 2015-06-30 | AU$337.65K ≈ $238.91K |
-72.62% |
| 2014-06-30 | AU$1.23 Million ≈ $872.45K |
+27.64% |
| 2013-06-30 | AU$966.00K ≈ $683.51K |
-17.44% |
| 2012-06-30 | AU$1.17 Million ≈ $827.85K |
+64.47% |
| 2011-06-30 | AU$711.40K ≈ $503.36K |
+1.09% |
| 2010-06-30 | AU$703.74K ≈ $497.94K |
-27.65% |
| 2009-06-30 | AU$972.64K ≈ $688.20K |
+36.19% |
| 2008-06-30 | AU$714.19K ≈ $505.34K |
-70.44% |
| 2007-06-30 | AU$2.42 Million ≈ $1.71 Million |
-1.87% |
| 2006-06-30 | AU$2.46 Million ≈ $1.74 Million |
+204.28% |
| 2005-06-30 | AU$809.16K ≈ $572.53K |
-69.29% |
| 2004-06-30 | AU$2.63 Million ≈ $1.86 Million |
-- |
About Algorae Pharmaceuticals Ltd
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up … Read more